Marijuana and Medicinal Cannabis

In November 2016, the Epilepsy Society of Australia issued a position statement concerning Marijuana and Medicinal Cannabis in the treatment of epilepsy.

Position statement

Epilepsy Society of Australia - Marijuana and Medicinal Cannabis in the Treatment of Epilepsy


Current literature

There is now data from randomised controlled trials of the efficacy of Epidioloex in Dravet Syndrome, Lennox-Gastaut syndrome and Tuberous Sclerosis. 

  • Devinsky et.al. (2016) Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med 376;21
  • Thiele et al. (2018) Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 391
  • Devinsky et al (2017). N. Engl J Med 2017;376:2011-20.
  • Devinsky et al (2018). N Engl J Med 2018;378:1888-97.
  • Cannabidiol (CBD) treatment in patients with seizures associated with Tuberous Sclerosis Complex: A randomised, double-blind, placebo-controlled, placebo-controlled phase 3 trial (GWPCARE6) (Abst. 1.293), 2019